STOCKHOLM, Sweden, 2 March 2026
Avia Pharma AB (“Avia”), a Sweden‑based pharmaceutical company focusing on OTC products across Northern Europe, today announced that it has completed the acquisition of the Swedish consumer health company Allderma AB (“Allderma”). The transaction closed on 27 February 2026 and represents another important step in Avia’s strategy to expand its presence within medically positioned consumer health and dermatology.
Allderma will add approximately EUR 14 million in annual sales to Avia’s growing portfolio and is expected to contribute positively to the company’s continued growth trajectory in the Nordic region and beyond. The acquisition further strengthens Avia’s commercial platform, brand portfolio and long‑term ability to scale differentiated consumer health products across its core European markets.
Through the acquisition, Avia gains access to Allderma’s rapidly growing portfolio of well‑established brands. Key products include Daxxin, a dermatology‑focused shampoo and shower formulation developed to support the treatment of dandruff, dry scalp and psoriasis‑related symptoms; Terclara, a pharmaceutical treatment for nail fungus with strong market recognition in Sweden and Norway; Hårkontroll, a food supplement designed to promote stronger hair growth and improved hair quality; and Lactiplus, a probiotic supplement supporting digestive health and overall wellbeing. Together, these products form a highly complementary portfolio that aligns closely with Avia’s focus on scientifically grounded, pharmacy‑recommended solutions.
The addition of Allderma’s brands enhances Avia’s dermatology offering while also expanding its presence within adjacent everyday health categories. Avia sees meaningful opportunities to further invest in brand development, geographic expansion and lifecycle management across the portfolio, supported by the company’s established Nordic infrastructure and growing European footprint.
“We are very impressed by the Allderma team, their entrepreneurial spirit and the strong growth the company has delivered in recent years,” said Jacob Calmvik, CEO of Avia Pharma. “The portfolio is highly complementary to our existing business and strengthens our position within dermatology and consumer health. We look forward to working with our new colleagues in the team to further develop the brands, expand their geographic reach and continue delivering high‑quality products that create real value for pharmacies, healthcare professionals and patients across our markets.”
For further information, please contact:
Jacob Calmvik, CEO
Email: Jacob.calmvik@aviapharma.se
Website: www.aviapharma.se
About Avia Pharma
Avia Pharma is a pharmaceutical company founded by professionals with extensive experience in the pharmaceutical and pharmacy sectors. The company operates throughout Northern Europe with offices in Stockholm, Helsinki, Munich and Greven, focusing on core therapeutic areas including dermatology, women’s health, allergy and everyday health. Through collaborations with international partners and its own brands, Avia Pharma markets pharmaceuticals, OTC products and medical devices that contribute to improved health and quality of life.
About Allderma
Allderma is a Sweden-based consumer healthcare company that develops, markets and sells pharmacy-distributed healthcare products across the Nordic region. Founded in 2001 and backed by 3iM Equity Partners since 2020, the company offers a diversified portfolio spanning OTC pharmaceuticals, medical devices, cosmetics and supplements addressing common conditions in dermatology and everyday health, supported by a strong pipeline and a track record of profitable growth.